Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Samples and Study Design
2.2. Serum Analysis of RF and ACPAs
2.3. Flow Cytometry
2.4. Luminescence Assays for Quantification of Plasmatic Levels of ATP and ADP
2.5. Cellular ATP Consumption Assay
2.6. Cytokine Levels in Serum and Supernatants
2.7. Cell Culture Preparation
2.8. Determination of IFNγ Secretion
2.9. Statistical Analysis
3. Results
3.1. Expression of CD39 and CD73 on Peripheral Blood Lymphocytes and Monocytes
3.2. Relationship between CD39 and CD73 Expression with the Disease Activity Indexes
3.3. Expression of CD39 and CD73 in Good Responders and Non-Good Responders to TCZ Treatment
3.4. Plasma ATP Levels in RA Patients at Baseline and during TCZ Treatment
3.5. The In Vitro Effects of IL-6 on CD39 and CD73 Expression in T Cells
3.6. The In Vitro Role of IL-6 in Influencing the Capacity of Effector T Cells to Produce IFNγ
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Feldmann, M.; Brennan, F.M.; Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397–440. [Google Scholar] [CrossRef] [PubMed]
- da Silva, J.L.G.; Passos, D.F.; Bernardes, V.M.; Leal, D.B.R. ATP and Adenosine: Role in the Immunopathogenesis of Rheumatoid Arthritis. Immunol. Lett. 2019, 214, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Varani, K.; Padovan, M.; Govoni, M.; Vincenzi, F.; Trotta, F.; Borea, P.A. The Role of Adenosine Receptors in Rheumatoid Arthritis. Autoimmun. Rev. 2010, 10, 61–64. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, D.; McNamee, E.N.; Idzko, M.; Gambari, R.; Eltzschig, H.K. Purinergic Signaling during Immune Cell Trafficking. Trends Immunol. 2016, 37, 399–411. [Google Scholar] [CrossRef] [PubMed]
- Antonioli, L.; Blandizzi, C.; Pacher, P.; Haskó, G. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. Pharmacol. Rev. 2019, 71, 345. [Google Scholar] [CrossRef]
- Robson, S.; Sévigny, J.; Zimmermann, H. The E-NTPDase Family of Ectonucleotidases: Structure Function Relationships and Pathophysiological Significance. Purinergic Signal 2006, 2, 409–430. [Google Scholar] [CrossRef]
- Colgan, S.P.; Eltzschig, H.K.; Eckle, T.; Thompson, L.F. Physiological Roles for Ecto-5′-Nucleotidase (CD73). Purinergic Signal 2006, 2, 351–360. [Google Scholar] [CrossRef]
- Bours, M.J.L.; Swennen, E.L.R.; Di Virgilio, F.; Cronstein, B.N.; Dagnelie, P.C. Adenosine 5′-Triphosphate and Adenosine as Endogenous Signaling Molecules in Immunity and Inflammation. Pharmacol. Ther. 2006, 112, 358–404. [Google Scholar] [CrossRef]
- Allard, B.; Longhi, M.S.; Robson, S.C.; Stagg, J. The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets. Immunol. Rev. 2017, 276, 121–144. [Google Scholar] [CrossRef]
- Bono, M.R.; Fernández, D.; Flores-Santibáñez, F.; Rosemblatt, M.; Sauma, D. CD73 and CD39 Ectonucleotidases in T Cell Differentiation: Beyond Immunosuppression. FEBS Lett. 2015, 589, 3454–3460. [Google Scholar] [CrossRef]
- Antonioli, L.; Pacher, P.; Vizi, E.S.; Haskó, G. CD39 and CD73 in Immunity and Inflammation. Trends Mol. Med. 2013, 19, 355–367. [Google Scholar] [CrossRef] [PubMed]
- Takenaka, M.C.; Robson, S.; Quintana, F.J. Regulation of the T Cell Response by CD39. Trends Immunol. 2016, 37, 427–439. [Google Scholar] [CrossRef] [PubMed]
- Peres, R.S.; Donate, P.B.; Talbot, J.; Cecilio, N.T.; Lobo, P.R.; Machado, C.C.; Lima, K.W.A.; Oliveira, R.D.; Carregaro, V.; Nakaya, H.I.; et al. TGF-β Signalling Defect Is Linked to Low CD39 Expression on Regulatory T Cells and Methotrexate Resistance in Rheumatoid Arthritis. J. Autoimmun. 2018, 90, 49–58. [Google Scholar] [CrossRef] [PubMed]
- Gupta, V.; Katiyar, S.; Singh, A.; Misra, R.; Aggarwal, A. CD39 Positive Regulatory T Cell Frequency as a Biomarker of Treatment Response to Methotrexate in Rheumatoid Arthritis. Int. J. Rheum. Dis. 2018, 21, 1548–1556. [Google Scholar] [CrossRef] [PubMed]
- Peres, R.S.; Liew, F.Y.; Talbot, J.; Carregaro, V.; Oliveira, R.D.; Almeida, S.L.; França, R.F.O.; Donate, P.B.; Pinto, L.G.; Ferreira, F.I.S.; et al. Low Expression of CD39 on Regulatory T Cells as a Biomarker for Resistance to Methotrexate Therapy in Rheumatoid Arthritis. Proc. Natl. Acad. Sci. USA 2015, 112, 2509–2514. [Google Scholar] [CrossRef] [PubMed]
- Zacca, E.R.; Amezcua Vesely, M.C.; Ferrero, P.V.; Acosta, C.D.V.; Ponce, N.E.; Bossio, S.N.; Mussano, E.; Onetti, L.; Cadile, I.; Acosta Rodríguez, E.V.; et al. B Cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and Increased CD39 Expression After Positive Response to Therapy. J. Mol. Biol. 2021, 433, 166687. [Google Scholar] [CrossRef] [PubMed]
- Thiolat, A.; Semerano, L.; Pers, Y.M.; Biton, J.; Lemeiter, D.; Portales, P.; Quentin, J.; Jorgensen, C.; Decker, P.; Boissier, M.-C.; et al. Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis. Arthritis Rheumatol. 2014, 66, 273–283. [Google Scholar] [CrossRef]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef]
- Sanmartí, R.; García-Rodríguez, S.; Álvaro-Gracia, J.M.; Andreu, J.L.; Balsa, A.; Cáliz, R.; Fernández-Nebro, A.; Ferraz-Amaro, I.; Gómez-Reino, J.J.; González-Álvaro, I.; et al. Actualización 2014 Del Documento de Consenso de La Sociedad Española de Reumatología Sobre El Uso de Terapias Biológicas En La Artritis Reumatoide. Reumatol. Clínica 2015, 11, 279–294. [Google Scholar] [CrossRef]
- Smolen, J.S.; Landewé, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; et al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann. Rheum. Dis. 2020, 79, 685. [Google Scholar] [CrossRef] [PubMed]
- van Riel, P.L.C.M.; Renskers, L. The Disease Activity Score (DAS) and the Disease Activity Score Using 28 Joint Counts (DAS28) in the Management of Rheumatoid Arthritis. Clin. Exp. Rheumatol. 2016, 34, S40–S44. [Google Scholar] [PubMed]
- Fransen, J.; van Riel, P.L.C.M. The Disease Activity Score and the EULAR Response Criteria. Rheum. Dis. Clin. 2009, 35, 745–757. [Google Scholar] [CrossRef] [PubMed]
- Helenius, M.; Jalkanen, S.; Yegutkin, G.G. Enzyme-Coupled Assays for Simultaneous Detection of Nanomolar ATP, ADP, AMP, Adenosine, Inosine and Pyrophosphate Concentrations in Extracellular Fluids. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2012, 1823, 1967–1975. [Google Scholar] [CrossRef] [PubMed]
- Murdoch, D.J.; Chow, E.D. A Graphical Display of Large Correlation Matrices. Am. Stat. 1996, 50, 178–180. [Google Scholar] [CrossRef]
- Botta Gordon-Smith, S.; Ursu, S.; Eaton, S.; Moncrieffe, H.; Wedderburn, L.R. Correlation of Low CD73 Expression on Synovial Lymphocytes with Reduced Adenosine Generation and Higher Disease Severity in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2015, 67, 545–554. [Google Scholar] [CrossRef] [PubMed]
- Kling, L.; Benck, U.; Breedijk, A.; Leikeim, L.; Heitzmann, M.; Porubsky, S.; Krämer, B.K.; Yard, B.A.; Kälsch, A.-I. Changes in CD73, CD39 and CD26 Expression on T-Lymphocytes of ANCA-Associated Vasculitis Patients Suggest Impairment in Adenosine Generation and Turn-Over. Sci. Rep. 2017, 7, 11683. [Google Scholar] [CrossRef]
- Ahmadi, P.; Hartjen, P.; Kohsar, M.; Kummer, S.; Schmiedel, S.; Bockmann, J.H.; Fathi, A.; Huber, S.; Haag, F.; Schulze Zur Wiesch, J. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73− Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes. Cells 2020, 9, 1750. [Google Scholar] [CrossRef]
- Petrelli, A.; van Wijk, F. CD8+ T Cells in Human Autoimmune Arthritis: The Unusual Suspects. Nat. Rev. Rheumatol. 2016, 12, 421–428. [Google Scholar] [CrossRef]
- Kawashiri, S.-Y.; Kawakami, A.; Okada, A.; Koga, T.; Tamai, M.; Yamasaki, S.; Nakamura, H.; Origuchi, T.; Ida, H.; Eguchi, K. CD4+CD25highCD127low/− Treg Cell Frequency from Peripheral Blood Correlates with Disease Activity in Patients with Rheumatoid Arthritis. J. Rheumatol. 2011, 38, 2517–2521. [Google Scholar] [CrossRef]
- Dwyer, K.M.; Hanidziar, D.; Putheti, P.; Hill, P.A.; Pommey, S.; McRae, J.L.; Winterhalter, A.; Doherty, G.; Deaglio, S.; Koulmanda, M.; et al. Expression of CD39 by Human Peripheral Blood CD4+CD25+ T Cells Denotes a Regulatory Memory Phenotype. Am. J. Transplant. 2010, 10, 2410–2420. [Google Scholar] [CrossRef]
- Niu, Q.; Cai, B.; Huang, Z.; Shi, Y.; Wang, L. Disturbed Th17/Treg Balance in Patients with Rheumatoid Arthritis. Rheumatol. Int. 2012, 32, 2731–2736. [Google Scholar] [CrossRef] [PubMed]
- Schneider, E.; Winzer, R.; Rissiek, A.; Ricklefs, I.; Meyer-Schwesinger, C.; Ricklefs, F.L.; Bauche, A.; Behrends, J.; Reimer, R.; Brenna, S.; et al. CD73-Mediated Adenosine Production by CD8 T Cell-Derived Extracellular Vesicles Constitutes an Intrinsic Mechanism of Immune Suppression. Nat. Commun. 2021, 12, 5911. [Google Scholar] [CrossRef] [PubMed]
- Ramakers, B.P.; Pickkers, P.; Deussen, A.; Rongen, G.A.; Van Den Broek, P.; Van Der Hoeven, J.G.; Smits, P.; Riksen, N.P. Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations. Curr. Drug Metab. 2008, 9, 679–685. [Google Scholar] [CrossRef] [PubMed]
- Löfgren, L.; Pehrsson, S.; Hägglund, G.; Tjellström, H.; Nylander, S. Accurate Measurement of Endogenous Adenosine in Human Blood. PLoS ONE 2018, 13, e0205707. [Google Scholar] [CrossRef] [PubMed]
- Meyer, A.; Wittekind, P.S.; Kotschenreuther, K.; Schiller, J.; von Tresckow, J.; Haak, T.H.; Kofler, D.M. Regulatory T Cell Frequencies in Patients with Rheumatoid Arthritis Are Increased by Conventional and Biological DMARDs but Not by JAK Inhibitors. Ann. Rheum. Dis. 2021, 80, e196. [Google Scholar] [CrossRef] [PubMed]
- Jarvis, L.B.; Rainbow, D.B.; Coppard, V.; Howlett, S.K.; Georgieva, Z.; Davies, J.L.; Mullay, H.K.; Hester, J.; Ashmore, T.; Van Den Bosch, A.; et al. Therapeutically Expanded Human Regulatory T-Cells Are Super-Suppressive Due to HIF1A Induced Expression of CD73. Commun. Biol. 2021, 4, 1186. [Google Scholar] [CrossRef] [PubMed]
- Parodi, A.; Battaglia, F.; Kalli, F.; Ferrera, F.; Conteduca, G.; Tardito, S.; Stringara, S.; Ivaldi, F.; Negrini, S.; Borgonovo, G.; et al. CD39 Is Highly Involved in Mediating the Suppression Activity of Tumor-Infiltrating CD8+ T Regulatory Lymphocytes. Cancer Immunol. Immunother. 2013, 62, 851–862. [Google Scholar] [CrossRef]
- Saze, Z.; Schuler, P.J.; Hong, C.-S.; Cheng, D.; Jackson, E.K.; Whiteside, T.L. Adenosine Production by Human B Cells and B Cell–Mediated Suppression of Activated T Cells. Blood 2013, 122, 9–18. [Google Scholar] [CrossRef]
- Chalmin, F.; Mignot, G.; Bruchard, M.; Chevriaux, A.; Végran, F.; Hichami, A.; Ladoire, S.; Derangère, V.; Vincent, J.; Masson, D.; et al. Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity 2012, 36, 362–373. [Google Scholar] [CrossRef]
- Regateiro, F.S.; Howie, D.; Nolan, K.F.; Agorogiannis, E.I.; Greaves, D.R.; Cobbold, S.P.; Waldmann, H. Generation of Anti-Inflammatory Adenosine Byleukocytes Is Regulated by TGF-β. Eur. J. Immunol. 2011, 41, 2955–2965. [Google Scholar] [CrossRef]
- Dienz, O.; Rincon, M. The Effects of IL-6 on CD4 T Cell Responses. Clin. Immunol. 2009, 130, 27–33. [Google Scholar] [CrossRef] [PubMed]
- Atsumi, T.; Sato, M.; Kamimura, D.; Moroi, A.; Iwakura, Y.; Betz, U.A.K.; Yoshimura, A.; Nishihara, M.; Hirano, T.; Murakami, M. IFN-γ Expression in CD8+ T Cells Regulated by IL-6 Signal Is Involved in Superantigen-Mediated CD4+ T Cell Death. Int. Immunol. 2009, 21, 73–80. [Google Scholar] [CrossRef] [PubMed]
- Ridgley, L.A.; Anderson, A.E.; Maney, N.J.; Naamane, N.; Skelton, A.J.; Lawson, C.A.; Emery, P.; Isaacs, J.D.; Carmody, R.J.; Pratt, A.G. IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. Front. Immunol. 2019, 10, 1535. [Google Scholar] [CrossRef] [PubMed]
- Qi, Y.; Huang, Y.; Wang, H.; Zhang, Y.; Bao, Y.; Sun, L.; Wu, Y.; Yu, C.; Song, Z.; Zheng, L.; et al. Elucidating the Crosstalk Mechanism between IFN-Gamma and IL-6 via Mathematical Modelling. BMC Bioinform. 2013, 14, 41. [Google Scholar] [CrossRef]
RA (n = 35) | C (n = 15) | ||||||
---|---|---|---|---|---|---|---|
n | Mean | SD | n | Mean | SD | p | |
Gender (women) | 28 | 12 | ns (#) | ||||
ACPA+ | 28 | ||||||
RF+ | 23 | ||||||
age (years) | 60.3 | 12.9 | 56.2 | 12.1 | ns (*) | ||
DAS28 | 5.4 | 1.2 | |||||
SDAI | 29.2 | 11.3 | |||||
CDAI | 27.4 | 10.8 | |||||
ESR (mm/h) | 39.6 | 22.4 | |||||
CRP (mg/dL) | 1.7 | 1.6 | |||||
Ig G (mg/dL) | 1182.1 | 280.7 | |||||
Ig A (mg/dL) | 294.1 | 178.8 | |||||
Ig M (mg/dL) | 167.3 | 179.4 | |||||
Monocytes (103/µL) | 0.7 | 0.3 | |||||
Neutrophils (103/µL) | 6.4 | 2.9 | |||||
Lymphocytes (103/µL) | 1.9 | 0.8 | |||||
Platelets (103/µL) | 293.0 | 80.9 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ortiz, M.A.; Diaz-Torné, C.; De Agustin, J.J.; Estrada, P.; Reina, D.; Hernandez, M.V.; Sang, H.; Zamora, C.; Cantó, E.; Corominas, H.; et al. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules 2024, 14, 1. https://doi.org/10.3390/biom14010001
Ortiz MA, Diaz-Torné C, De Agustin JJ, Estrada P, Reina D, Hernandez MV, Sang H, Zamora C, Cantó E, Corominas H, et al. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules. 2024; 14(1):1. https://doi.org/10.3390/biom14010001
Chicago/Turabian StyleOrtiz, María Angels, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hector Corominas, and et al. 2024. "Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response" Biomolecules 14, no. 1: 1. https://doi.org/10.3390/biom14010001